Authors/Disclosures
|
Kathleen E. Clarence-Smith, MD, PhD, FAAN
(KM Pharmaceuticals Consulting)
|
Dr. Clarence-Smith has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Riverside Pharmaceutical Corporation. Dr. Clarence-Smith has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for KMPHC. Dr. Clarence-Smith has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Chase Therapeutics Corporation. Dr. Clarence-Smith has received stock or an ownership interest from Chase Therapeutics Corporation. Dr. Clarence-Smith has received stock or an ownership interest from Riverside Pharmaceuticals Corporation. |
|
Vivienne Shen
|
Vivienne Shen has received personal compensation for serving as an employee of Lundbeck. |
|
Christine B. Hunter, RN, BSN
(PDCMDC)
|
No disclosure on file |
|
Joseph Jankovic, MD, FAAN
(Baylor College of Medicine)
|
Dr. Jankovic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Revance. Dr. Jankovic has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance, Allergan. The institution of Dr. Jankovic has received research support from Baylor College of Medicine. Dr. Jankovic has received research support from Abbvie. The institution of Dr. Jankovic has received research support from Abbvie. |
|
Lara W. Katzin, MD
(Colorado Permanente Medical Group)
|
Dr. Katzin has nothing to disclose. |